- Home
- KALA vs CIF Comparison
KALA vs CIF Comparison
Compare KALA & CIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- CIF
- Stock Information
- Founded
- KALA 2009
- CIF 1988
- Country
- KALA United States
- CIF United States
- Employees
- KALA N/A
- CIF N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- CIF Trusts Except Educational Religious and Charitable
- Sector
- KALA Health Care
- CIF Finance
- Exchange
- KALA Nasdaq
- CIF Nasdaq
- Market Cap
- KALA 26.2M
- CIF 30.9M
- IPO Year
- KALA 2017
- CIF N/A
- Fundamental
- Price
- KALA $3.52
- CIF $1.71
- Analyst Decision
- KALA Strong Buy
- CIF
- Analyst Count
- KALA 3
- CIF 0
- Target Price
- KALA $14.00
- CIF N/A
- AVG Volume (30 Days)
- KALA 55.2K
- CIF 43.9K
- Earning Date
- KALA 05-14-2025
- CIF 01-01-0001
- Dividend Yield
- KALA N/A
- CIF 10.11%
- EPS Growth
- KALA N/A
- CIF N/A
- EPS
- KALA N/A
- CIF N/A
- Revenue
- KALA N/A
- CIF N/A
- Revenue This Year
- KALA N/A
- CIF N/A
- Revenue Next Year
- KALA N/A
- CIF N/A
- P/E Ratio
- KALA N/A
- CIF N/A
- Revenue Growth
- KALA N/A
- CIF N/A
- 52 Week Low
- KALA $2.92
- CIF $1.47
- 52 Week High
- KALA $11.20
- CIF $1.77
- Technical
- Relative Strength Index (RSI)
- KALA 42.83
- CIF 55.37
- Support Level
- KALA $3.67
- CIF $1.67
- Resistance Level
- KALA $4.16
- CIF $1.77
- Average True Range (ATR)
- KALA 0.31
- CIF 0.02
- MACD
- KALA 0.05
- CIF -0.00
- Stochastic Oscillator
- KALA 34.20
- CIF 66.67
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About CIF MFS Intermediate High Income Fund
Mfs Intermediate High Income Fund is a United States based diversified closed-end management investment company. Its investment objective is to seek high current income but may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment grade corporate bonds, government securities and other securities.